E-viri
Recenzirano
Odprti dostop
-
von Drygalski, Annette; Chowdary, Pratima; Kulkarni, Roshni; Susen, Sophie; Konkle, Barbara A.; Oldenburg, Johannes; Matino, Davide; Klamroth, Robert; Weyand, Angela C.; Jimenez-Yuste, Victor; Nogami, Keiji; Poloskey, Stacey; Winding, Bent; Willemze, Annemieke; Knobe, Karin
The New England journal of medicine, 01/2023, Letnik: 388, Številka: 4Journal Article
Efanesoctocog alfa is a factor VIII fusion agent that permits weekly treatment to prevent bleeding. In this study, two thirds of treated patients had no bleeding episodes, and the annualized bleeding rate fell by 77%.
